Developing a Vaccine for Ebola

The Ebola vaccine projects – EBOVAC1, EBOVAC2, EBOVAC3EBODAC and EBOMAN – are a series of trials and associated projects which aim to assess a novel two-dose preventive vaccine regimen against Ebola Virus Disease (EVD). In a two-dose vaccine regimen, individuals are given a first dose to prime the immune system, and then a second dose which is intended to enhance the immune response and increase the duration of the response.

Between them the EBOVAC1EBOVAC2 and EBOVAC3 projects are assessing – through several clinical trials conducted in phases in Europe and Africa – the safety, tolerability and immunogenicity of the vaccine regimen in response to the public health need raised by the West African Ebola epidemic of 2014-2016.

Find out more about the trials:




EBOVAC1, EBOVAC2 and EBOVAC3 are working closely with the EBODAC vaccine deployment, acceptance and compliance project, and the EBOMAN vaccine manufacture capability project.

Find out more about these projects:

EBODAC – Vaccine deployment, acceptance and compliance

EBOMAN – Vaccine manufacture capability

Ebola signs in Freetown, Sierra Leone (Dr D Watson-Jones)

Ebola signs in Freetown, Sierra Leone (Credit: Dr D Watson-Jones)

The Ebola vaccine projects are part of the Innovative Medicines Initiative Ebola+ programme

These projects have received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement EBOVAC1 (grant nr. 115854), EBOVAC2 (grant nr. 115861), EBOVAC3 (grant nr. 800176), EBOMAN (grant nr. 115850) and EBODAC (grant nr. 115847). This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and European Federation of Pharmaceutical Industries and Associations (EFPIA).
Copyright © 2021 Ebovac | Terms and Conditions | WordPress development by Toast.